2020 Webinar: Chronic Hepatitis C 500: The Advanced Course
Recorded On: 12/02/2020
Many HCV-infected patients suffer from decompensated cirrhosis. Aside from appropriate care of their cirrhosis, these patients may benefit from therapy, irrespective of liver transplant candidacy. Providers outside of transplant centers, should be knowledgeable about pertinent aspects of liver transplants for their patients. Finally, several groups have reported unusual genotype subtypes which are less responsive to existing DAA regimens. This webinar is designed for the experienced HCV-treatment provider.
Brian L. Pearlman, MD is Medical Director for Wellstar Atlanta Medical Center’s Center for Hepatitis C in Atlanta Georgia. He is also Professor of Medicine at the Medical College of Georgia and Professor of Medicine at Emory School of Medicine. Dr. Pearlman completed his medical degree at the University of Miami, Florida and his post-graduate training included both Diagnostic Radiology at University of Texas-Southwestern and Internal Medicine at Baylor University-Dallas, Texas.
Dr. Pearlman is Faculty for the American College of Physicians (FACP), Fellow of the American Association for the Study of Liver Diseases (FAASLD), and members of the American Academy of HIV Medicine, and the American Gastroenterological Association. He sat on the Board of Directors for The American Liver Foundation’s Southeast Chapter. Dr. Pearlman is widely published in leading journals such as The Lancet, Gastroenterology, HEPATOLOGY, The American Journal of Gastroenterology, The Lancet Infectious Disease, Clinical Infectious Diseases and The American Journal of Medicine.
Dr. Pearlman is active in both patient care and in teaching physicians. He has been the recipient of numerous teaching awards, and also an active investigator in multiple hepatitis C-related trials, some of which are in collaboration with the CDC’s Division of Viral Hepatitis.
Preeti A. Reshamwala
Preeti A. Reshamwala, MD is a Distinguished Physician in Transplant Hepatology at Emory University School of Medicine. She is the director of The Fatty Liver Clinic, and the program director for the Transplant Hepatology Fellowship Program.
Dr. Reshamwala has participated in over 21 clinical trials on the treatment of Hepatitis C. She co-directs the management and treatment of patients with hepatitis C who are on the waitlist for liver transplantation at Emory University, and hepatitis C treatment for patients after transplantation. She has been an advocate for using hepatitis C positive donors for liver transplant recipients who have not been exposed to Hepatitis C.
Jean-Michel Pawlotsky, MD, PhD is professor of medicine at the University of Paris-Est. He is the director of the National Reference Center for Viral Hepatitis B, C and D and of the Department of Virology at the Henri Mondor University Hospital in Créteil, France, and director of research team “Viruses-Hepatology-Cancers“ at the Mondor Institute of Biomedical Research (INSERM U955). He focuses on teaching and research in virology (primarily hepatitis viruses) and liver oncology. Dr. Pawlotsky earned his medical degree in Hepatology and Gastroenterology in 1992. In addition, he earned a Thesis in molecular virology from the University of Paris, France, and he is a graduate in virology from the Pasteur Institute in Paris and microbiology from the University of Paris. Dr. Pawlotsky has been acting as the Secretary General of the European Association for the Study of the Liver (EASL) between 2005 and 2009.
Dr. Pawlotsky is a member of the Strategic Committee of the National Agency for Research on AIDS and Viral Hepatitis (ANRS). He has been an associate editor of HEPATOLOGY, the official journal of the American Association for the Study of Liver Diseases (AASLD), between 2001 and 2006, and an associate editor of Gastroenterology, the official journal of the American Gastroenterological Association (AGA), between 2011 and 2016. Dr. Pawlotsky’s noted career contributions include the publication of over 500 articles and book chapters in his areas of expertise and over 650 invited lectures at international meetings.
Omar Massoud (Moderator)
Omar Massoud, MD, PhD, FAASLD is an associate professor of medicine at the University of Alabama at Birmingham. He is the director of clinical liver research at the University of Alabama Liver Center. He is a member of the AASLD Publication Committee and Hepatitis C Special Interest Group Steering Committee. He earned his Doctor of Medicine degree from Al-Azhar University, Cairo, Egypt. He completed residency in Internal Medicine at Case Western Reserve University, Cleveland, Ohio, followed by Fellowship in Gastroenterology and Hepatology at the Medical College of Wisconsin, Milwaukee, Wisconsin. He completed a fellowship in Transplant Hepatology at Mayo Clinic, Rochester, Minnesota.
Dr. Massoud was the PI of the large CDC study on Birth Cohort HCV screening (2011-2016). The results of this study lead to change in HCV screening national guidelines. He is also the PI of several government and industry sponsored studies on HCV and NASH. He has numerous publications and presentations on HCV and NASH. He mentored many trainees and young faculty throughout their career.
Photo of Omar Massoud, MD, PhD, FAASLD